NNRTI

(redirected from non-nucleoside reverse transcriptase inhibitor)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
Related to non-nucleoside reverse transcriptase inhibitor: NRTI, nucleotide reverse transcriptase inhibitors
AcronymDefinition
NNRTINon-Nucleoside Reverse Transcriptase Inhibitor
References in periodicals archive ?
Other factors associated with severe hepatotoxicity in this study were use of nevirapine-containing drugs, which were associated in those taking a non-nucleoside reverse transcriptase inhibitor with both early (OR 4.
SUSTIVA is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that was originally approved in the US in 1998 to treat HIV-1 infected children three years of age or older and weighing at least 10 kg.
New precautions have been added to the labeling for Viramune, a non-nucleoside reverse transcriptase inhibitor (NNRTI or "non-nuke").
Eviplera combines Gilead's Truvada (emtricitabine and tenofovir disoproxil (as fumarate)) with Tibotec Pharmaceuticals' non-nucleoside reverse transcriptase inhibitor Edurant (rilpivirine (as hydrochloride)).
Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for marketing approval for the fixed-dose combination of Truvada (emtricitabine and tenofovir disoproxil (as fumarate)) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine (as hydrochloride)) for the treatment of HIV-1 infection in adults.
For example, Tibotec has 2 drugs in parallel development, a protease inhibitor (PI) with good activity against PI-resistant virus and a new non-nucleoside reverse transcriptase inhibitor (NNRTI) that overcomes viral resistance to other drugs of this type.
It at first restricted entry to persons with viral loads over 10,000 and CD4 counts under 100 -- plus documented treatment failure with at least two protease inhibitors or one PI and one non-nucleoside reverse transcriptase inhibitor (NNRTI).
3 September 2010 - Irish Tibotec Pharmaceuticals, part of Johnson & Johnson (NYSE: JNJ), said today it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TMC278 (rilpivirine, as hydrochloride), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV.
But many clinicians are still unsure of whether to use abacavir as part of a first treatment regimen or to save it for later, or whether to combine it with a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor.
Full browser ?